Mette Y.
- Country
- Denmark
- Department
- Department of Oncology
Research Overview
- Phase 3 Randomized Double-Blind Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in HER2-Negative Advanced Gastric or GEJ Adenocarcinoma
- Evaluation of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin in Locally Advanced Colon Cancer: A Comparative Study with Standard Treatment
- Evaluation of Trastuzumab with Chemotherapy and Pembrolizumab in First-Line Treatment of HER2-Positive Esophageal Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 3 of 27 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating gastric and gastroesophageal junction (GEJ) cancers, with particular focus on innovative therapeutic approaches combining chemotherapy and immunotherapy.
- Advanced Gastric Cancer Treatment
- GEJ Adenocarcinoma Management
- Neoadjuvant-Adjuvant Therapy
Their research encompasses both early-stage and advanced disease states in gastric oncology.
Esophageal Cancer Research
Focused on developing treatment strategies for esophageal squamous cell carcinoma, particularly investigating targeted therapies in combination with standard treatments.
- HER2-Positive ESCC Treatment
- Immunotherapy Applications
- Targeted Therapeutic Approaches
The investigator explores innovative combinations of targeted agents with conventional treatments.
Colorectal Oncology
Expertise in locally advanced colon cancer treatment, with specific interest in neoadjuvant therapeutic strategies and their impact on patient outcomes.
- Neoadjuvant Chemotherapy
- Advanced Colon Cancer Management
- Disease-Free Survival Studies
Their work focuses on optimizing treatment sequences in locally advanced disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.